Oral lichen planus and intake of drugs metabolized by polymorphic cytochrome P450 enzymes

Oral Diseases

Volumn 9, Issue 4, 2003, Pages 177-187

  Kragelund, Camilla ^a   Thomsen, C E ^a   Bardow, A ^a   Pedersen, A M ^a   Nauntofte, B ^a   Reibel, J ^a   Torpet, L A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CYP; Genetic polymorphism; Oral adverse drug reaction

Indexed keywords

ANALGESIC AGENT; ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; ANTIULCER AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PSYCHOTROPIC AGENT; SEX HORMONE; THROMBIN INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENETIC VARIABILITY; HUMAN; HYPOTHESIS; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; MOUTH DISEASE; POLYPHARMACY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE; DRUG THERAPY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; POLYPHARMACY; SEX FACTORS; VARIATION (GENETICS);

EID: 0037707481     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1601-0825.2003.02892.x     Document Type: Article

References (71)

1. Axell T (1976). A prevalence study of oral mucosal lesions in an adult Swedish population. Odontol Revy 27: 1-103.
2. Axell T, Rundquist L (1987). Oral lichen planus - a demographic study. Community Dent Oral Epidemiol 15: 52-56.
3. Bergman U, Wiholm BE (1981). Drug-related problems causing admission to a medical clinic. Eur J Clin Pharmacol 20: 193-200.
4. Bjerrum L, Sogaard J, Hallas J et al (1998). Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 54: 197-202.
5. Bleau AM, Fradette C, El Kadi AO et al (2001). Cytochrome P450 down-regulation by serum from humans with a viral infection and from rabbits with an inflammatory reaction. Drug Metab Dispos 29: 1007-1012.
6. Blomeke B, Bennett WP, Harris CC et al (1997). Serum, plasma and paraffin-embedded tissues as sources of DNA for studying cancer susceptibility genes. Carcinogenesis 18: 1271-1275.
7. Blouin RA, Farrell GC, Ioannides C et al (1999). Impact of diseases on detoxication. J Biochem Mol Toxicol 13: 215-218.
8. Boitier E, Beaune P (2000). Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update. Clin Rev Allergy Immunol 18: 215-239.
9. Bouchardy C, Benhamou S, Dayer P (1996). The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 56: 251-253.
10. Bravard P, Barbet M, Eich D et al (1983). Captopril induced lichenoid eruption. Ann Dermatol Venereol 110: 433-438.
11. Brinn R, Brosen K, Gram LF et al (1986). Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 22: 194-197.
12. Brosen K, Nielsen PN, Brusgaard K et al (1994). CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 47: 221-225.
13. Burrows SR, Khanna R, Moss DJ (1999). Direct alloreactivity by human cytotoxic T lymphocytes can be inhibited by altered peptide ligand antagonism. Blood 93: 1020-1024.
14. Chainani-Wu N, Silverman S Jr, Lozada-Nur F et al (2001). Oral lichen planus: patient profile, disease progression and treatment responses. J Am Dent Assoc 132: 901-909.
15. Clemente MG, Meloni A, Obermayer-Straub P et al (1998). Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 114: 324-328.
16. Dalekos GN, Wedemeyer H, Obermayer-Straub P et al (1999). Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 30: 366-375.
17. Farrell GC (1987). Drug metabolism in extrahepatic diseases. Pharmacol Ther 35: 375-404.
18. Figueiredo LC, Carrilho FJ, de Andrage HF et al (2002). Oral lichen planus and hepatitis C virus infection. Oral Dis 8: 42-46.
19. Firth NA, Reade PC (1989). Angiotensin-converting enzyme inhibitors implicated in oral mucosal lichenoid reactions. Oral Surg Oral Med Oral Pathol 67: 41-44.
20. Fischer GF, Mayr WR (2001). Molecular genetics of the HLA complex. Wien Klin Wochenschr 113: 814-824.
21. Flockhart DA (2002). Drug table. http://medicine.iupui.edu/flockhart/(updated 2002/04/29).
22. Gorski JC, Hall SD, Becker P et al (2000). In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther 67: 32-43.
23. Grinspan D, Diaz J, Villapol LO et al (1966). Lichen ruber planus de la muquese buccale, sone association a un diabete. Bull Soc Fr Dermatol Syphiligr 73: 898-899.
24. Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED) (1990). Lichen planus and liver diseases: a multicentre case-control study. BMJ 300: 227-230.
25. Halevy S, Grunwald MH, Feuerman EJ et al (1986). Lichenoid eruption due to hydrochlorothiazide. Diagnostic aid of macrophage migration inhibition factor (MIF) test. Ann Allergy 56: 402-405.
26. Halevy S, Shai A (1993). Lichenoid drug eruptions. J Am Acad Dermatol 29: 249-255.
27. Hasler JA, Estabrook R, Murray M et al (1999). Human cytochromes P450. Mol Aspects Med 20: 1-137.
28. Hawk JLM (1980). Lichenoid drug eruption induced by propranolol. Clin Exp Dermatol 5: 93-96.
29. Hayes EM (2001). Cytochrome P-450 and drug interactions. Drugs and the various cytochrome P-450 systems that play a role in their metabolism. http://www.edhayes.com/CY.P450-1.html
30. Henriksson E, Mattsson U, Hakansson J (1995). Healing of lichenoid reactions following removal of amalgam. A clinical follow-up. J Clin Periodontol 22: 287-294.
31. Ingafou M, Porter SR, Scully C et al (1998). No evidence of HCV infection or liver disease in British patients with oral lichen planus. Int J Oral Maxillofac Surg 27: 65-66.
32. Ingelman-Sundberg M (2001). Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482: 11-19.
33. Jaeger JJ, Hedegaard H (2002). Den danske hepatitis C ljemmeside http://home3.inet.tele.dk/omni/hepatitissmittede.htm
34. Jackson JE, Ramsdell JW, Renvall M et al (1989). Reliability of drug histories in a specialized geriatric outpatient clinic. J Gen Intern Med 4: 39-43.
35. Johnson MD, Newkirk G, White JR Jr (1999). Clinically significant drug interactions. Postgrad Med 105: 193-196.
36. Lamey PJ, Gibson J, Barclay SC et al (1990). Grinspan's syndrome: a drug-induced phenomenon? Oral Surg Oral Med Oral Pathol 70,: 184-185.
37. Lamey PJ, McCartan BE, MacDonald DG et al (1995). Basal cell cytoplasmic autoantibodies in oral lichenoid reactions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79: 44-49.
38. Longuemaux S, Delomenie C, Gallou C et al (1999). Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res 59: 2903-2908.
39. Manns MP, Griffin KJ, Sullivan KF et al (1991). LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 88: 1370-1378.
40. McCartan BE, McCreary CE (1997). Oral lichenoid drug eruptions. Oral Dis 3: 58-63.
41. van der Meij EH, Reibel J, Slootweg PJ et al (1999). Interobserver and intraobserver variability in the histologic assessment of oral lichen planus. J Oral Pathol Med 28: 274-277.
42. van der Meij EH, van der Waal, I (2000). Hepatitis C virus infection and oral lichen planus: a report from The Netherlands. J Oral Pathol Med 29: 255-258.
43. van der Meij EH, Schepman KP, Plonait DR et al (2002). Interobserver and intraobserver variability in the clinical assessment of oral lichen planus. J Oral Pathol Med 31: 95-98.
44. Morgan ET (1997). Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29: 1129-1188.
45. Morgan ET (2001). Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 29: 207-212.
46. Muratori L, Parola M, Ripalti A et al (2000). Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 46: 553-561.
47. Nebert DW (1999). Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 56: 247-258.
48. Nelson D (2000). Cytochrome P450s in humans. http://dnelson.utmem.edu/P450/eet.htm
49. Pindborg JJ, Reichart PA, Smith CJ et al (1997). WHO. Histological typing of cancer and precancer of the oral mucosa. Berlin: Springer-verlag.
50. Pollock BG, Wylie M, Stack JA et al (1999). Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 39: 936-940.
51. Potts AJ, Hamburger J, Scully C (1987). The medication of patients with oral lichen planus and the association of nonsteroidal anti-inflammatory drugs with erosive lesions. Oral Surg Oral Med Oral Pathol 64: 541-543.
52. Reinhardt LA, Wilkin JK, Kirkendall WM (1983). Lichenoid eruption produced by captopril. Cutis 31: 98-99.
53. Rendic S (2002). Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34: 83-448.
54. Robertson WD, Wray D (1992). Ingestion of medication among patients with oral keratoses including lichen planus. Oral Surg Oral Med Oral Pathol 74: 183-185.
55. Roy KM, Dickson EM, Staines KS et al (2000). Hepatitis C virus and oral lichen planus/lichenoid reactions: lack of evidence for an association. Clin Lab 46: 251-254.
56. Scully C, Beyli M, Ferreiro MC et al (1998). Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med 9: 86-122.
57. Shedlofsky SI, Israel BC, McClain CJ et al (1994). Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 94: 2209-2214.
58. Sieben S, Baron JM, Blomeke B et al (1999). Multiple cytochrome P450-isoenzymes mRNA are expressed in dendritic cell. Int Arch Allergy Immunol 118: 358-361.
59. Siegle I, Fritz P, Eckhardt K et al (2001). Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11: 237-245.
60. Silverman S Jr, Gorsky M, Lozada-Nur F (1985). A prospective follow-up study of 570 patients with oral lichen planus: persistence, remission, and malignant association. Oral Surg Oral Med Oral Pathol 60: 30-34.
61. Silverman S Jr, Gorsky M, Lozada-Nur F et al (1991). A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol 72: 665-670.
62. Spagnoli A, Ostino G, Borga AD et al (1989). Drug compliance and unreported drugs in the elderly. J Am Geriatr Soc 37: 619-624.
63. Tamminga WJ, Wemer J, Oosterhuis B et al (1999). CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55: 177-184.
64. Thompson DF, Skaehill PA (1994). Drug-induced lichen planus. Pharmacotherapy 14: 561-571.
65. Thorn JJ, Holmstrup P, Rindum J et al (1988). Course of various clinical forms of oral lichen planus. A prospective follow-up study of 611 patients. J Oral Pathol 17: 213-218.
66. Van den Haute V, Antoine JL, Lachapelle JM (1989). Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples. Dermatologica 179: 10-13.
67. Vondracek M, Xi Z, Larsson P et al (2001). Cytochrome P450 expression and related metabolism in human buccal mucosa. Carcinogenesis 22: 481-488.
68. Wolkenstein P, Tan C, Lecoeur S et al (1998). Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem Biol Interact 113: 39-50.
69. Yokose T, Doy M, Taniguchi T et al (1999). Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues. Virchows Arch 434: 401-411.
70. Zain RB, Ikeda N, Razak IA et al (1997). A national epidemiological survey of oral mucosal lesions in Malaysia. Community Dent Oral Epidemiol 25: 377-383.
71. Zhou LX, Pihlstrom B, Hardwick JP et al (1996). Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia. Clin Pharmacol Ther 60: 191-198.